Evidence map›Paper›PMID 29155869›Full record

ArticlePloS one2017

NF-κB pathways are involved in M1 polarization of RAW 264.7 macrophage by polyporus polysaccharide in the tumor microenvironment.

Chun-Ping Liu, Xian Zhang, Qing-Long Tan, Wen-Xing Xu, Chang-Yuan Zhou, Min Luo, Xiong Li, Run-Yue Huang, Xing Zeng

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. [YTHDF3 Regulates Macrophage Activation: Investigation of the Mechanisms Involved].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025
    Article
  8. Article
  9. Article
  10. Parishin E from ginger-processedFrontiers in pharmacology · 2025
    Article
  11. Engineering in life sciences · 2025
    Review
  12. Review
  13. Review
  14. Article
  15. HomogeneousPharmaceutical biology · 2024
    Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Chun-Ping LiuDepartment of Integrated Chinese medicine immunization and Section Rheumatology Research, The Second Affiliated Hospital, Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China.
Xian ZhangDepartment of Integrated Chinese medicine immunization and Section Rheumatology Research, The Second Affiliated Hospital, Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China.
Qing-Long TanDepartment of Integrated Chinese medicine immunization and Section Rheumatology Research, The Second Affiliated Hospital, Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China.
Wen-Xing XuDepartment of Integrated Chinese medicine immunization and Section Rheumatology Research, The Second Affiliated Hospital, Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China.
Chang-Yuan ZhouDepartment of Integrated Chinese medicine immunization and Section Rheumatology Research, The Second Affiliated Hospital, Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China.
Min LuoDepartment of Integrated Chinese medicine immunization and Section Rheumatology Research, The Second Affiliated Hospital, Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China.
Xiong LiDepartment of Integrated Chinese medicine immunization and Section Rheumatology Research, The Second Affiliated Hospital, Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China.
Run-Yue HuangDepartment of Integrated Chinese medicine immunization and Section Rheumatology Research, The Second Affiliated Hospital, Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China.ORCID http://orcid.org/0000-0002-3223-7657
Xing ZengDepartment of Integrated Chinese medicine immunization and Section Rheumatology Research, The Second Affiliated Hospital, Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China.
Guangzhou University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bladder cancer is one of the most malignant tumors closely associated with macrophages. Polyporus polysaccharide (PPS) has shown excellent efficacy in treating bladder cancer with minimal side effects. However, the molecular mechanisms underlying the effects of PPS in inhibiting bladder cancer remain unclear. In this study, we used macrophages cultured alone or with T24 human bladder cancer cell culture supernatant as study models. We found that PPS enhanced the activities of IFN-γ-stimulated RAW 264.7 macrophages, as shown by the release of inducible nitric oxide synthase (INOS), secretion of tumor necrosis factor (TNF)-α and interleukin (IL)-6, phagocytosis activity, as well as expression of M1 phenotype indicators, such as CD40, CD284 and CD86. PPS acted upstream in activation cascade of nuclear factor (NF)-κB signaling pathways by interfering with IκB phosphorylation. In addition, PPS regulated NF-κB (P65) signaling by interfering with Toll-like receptor (TLR)-4, INOS and cyclooxygenase (COX)-2. Our results indicate that PPS activates macrophages through TLR4/NF-κB signaling pathways.

Indexed as

AnimalsAntigens, CDAntineoplastic AgentsCell LineCell Line, TumorCulture Media, ConditionedCyclooxygenase 2Epithelial CellsFungal PolysaccharidesGene Expression RegulationHumansInterferon-gammaInterleukin-6Macrophage ActivationMacrophagesMiceAntigens, CDAntineoplastic AgentsCulture Media, ConditionedCyclooxygenase 2Fungal PolysaccharidesInterferon-gammaInterleukin-6interleukin-6, mouseNF-kappa BNitric Oxide Synthase Type IINos2 protein, mousePtgs2 protein, mouseTlr4 protein, mouseToll-Like Receptor 4Tumor Necrosis Factor-alpha

Identifiers

PMID29155869
PMCPMC5695768
OpenAlexW2770839628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.